Early clinical study of an intermittent schedule for maytansine (NSC-153858)

R. T. Eagan, J. N. Ingle, J. Rubin, S. Frytak, C. G. Moertel

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m2 on days 1, 3, and 5 (total dose, 2.25 mg/m2) repeated every 4 weeks is recommended for Phase II trials.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalUnknown Journal
Volume60
Issue number1
DOIs
StatePublished - Jan 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Early clinical study of an intermittent schedule for maytansine (NSC-153858)'. Together they form a unique fingerprint.

  • Cite this

    Eagan, R. T., Ingle, J. N., Rubin, J., Frytak, S., & Moertel, C. G. (1978). Early clinical study of an intermittent schedule for maytansine (NSC-153858). Unknown Journal, 60(1), 93-96. https://doi.org/10.1093/jnci/60.1.93